29,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Between March 1, 2016, and March 12, 2020, 383 patients were enrolled and randomly assigned to the intervention or control group. 5 key findings →
Design: randomized controlled trial Participants: 383 Evidence: high
Full summary, score breakdown and related studies → Original source
We included 49 studies, with sample sizes ranging from 14 to 91,948 participants (>200,000 total) and a median sample size of 145. 1 key finding →
Design: meta-analysis Participants: 49 Evidence: high
Full summary, score breakdown and related studies → Original source
A total of 57 articles were included in the review, including 3182 participants. 4 key findings →
Design: meta-analysis Participants: 3,182 Evidence: high
Full summary, score breakdown and related studies → Original source
This study provides corroborating evidence that solanezumab does not slow cognitive decline in preclinical AD as exhibited with a computerized cognitive assessment with some evidence that solanezumab may exacerbate cognition on select digital outcomes. 4 key findings →
Design: longitudinal study Participants: 1,117 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The iCST app was deemed usable and enjoyable. 5 key findings →
Design: randomized controlled trial Participants: 31 Evidence: high
Full summary, score breakdown and related studies → Original source
However, crossword puzzles might result in cognitively beneficial remodeling between the DMN and other networks in more severely impaired MCI subjects, parallel to the observed clinical benefits. 4 key findings →
Participants: 107 Evidence: high
Full summary, score breakdown and related studies → Original source
The 3-minute START task offers a means of supporting cognitive health in older adults and could be used at scale and within a precision medicine approach to reduce risk of cognitive decline in a targeted way. 1 key finding →
Design: randomized controlled trial Participants: 6,544 Evidence: high
Full summary, score breakdown and related studies → Original source
Well-designed and executed RCTs are needed to confirm our findings on stroke and to have more scientific evidence available for the other neurological diseases. 4 key findings →
Participants: 2,335 Evidence: high
Full summary, score breakdown and related studies → Original source
The BTS implemented in MYB is focused on maximizing adherence and engagement with CCT over the short and long term in the setting of a fully digital trial, which, if successful, could be delivered economically at scale. 1 key finding →
Design: randomized controlled trial Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source
The addition of CS to the SPEP was a safe and effective method to gain statistically significant improvements in cognition, balance, FM, UEMS, IADL, and reduction in depression in PwAD. 2 key findings →
Participants: 75 Evidence: high
Full summary, score breakdown and related studies → Original source
Multidomain lifestyle modification is considered an effective intervention for dementia prevention due to its multifactorial nature. 2 key findings →
Design: randomized controlled trial Participants: 40 Evidence: high
Full summary, score breakdown and related studies → Original source
Despite the large number of commercially available mobile health applications, the magnitude of the scientific evidence base remains very limited. 3 key findings →
Design: systematic review Participants: 21 Evidence: high
Full summary, score breakdown and related studies → Original source
The use of ecologically oriented approaches with virtual reality (VR) depicting instrumental activities of daily living (IADL) is a promising approach for interventions on acquired brain injuries. 2 key findings →
Design: randomized controlled trial Participants: 17 Evidence: high
Full summary, score breakdown and related studies → Original source
Participants in the experimental group had better overall subjective memory, subjective retrospective memory and global quality of life, with fewer depressive symptoms than those in the control group 3 months following the program. 3 key findings →
Design: randomized controlled trial Participants: 15 Evidence: high
Full summary, score breakdown and related studies → Original source
Our sample had a mean age of 66.8 (SD = 5.3) years, a mean HAM-D score of 19.4 (SD = 7.5), and a mean PHQ-9 score of 18.0 (SD = 6.3). 5 key findings →
Design: randomized controlled trial Participants: 28 Evidence: high
Full summary, score breakdown and related studies → Original source
The findings of this cohort study suggest that smartphones could offer a feasible, reliable, valid, and scalable solution for remote evaluations of FTLD and may improve early detection. 4 key findings →
Design: cohort study Participants: 258 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Prior work has shown that the video component significantly contributes to quality and satisfaction of the visit.3 In addition to the technology itself, patients need to know what to expect for their telehealth appointments. 2 key findings →
Design: randomized controlled trial Participants: 5,000 Evidence: high
Full summary, score breakdown and related studies → Original source
The care of people with dementia is largely provided by informal caregivers (e.g., family, friends), which can present significant challenges and increase caregivers' burden. 5 key findings →
Participants: 16 Evidence: high
Full summary, score breakdown and related studies → Original source
MemScreen outperformed traditional tests in identifying MCI in both general and clinical populations. 3 key findings →
Design: cohort study Participants: 2,118 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Digital cognitive assessments have rapidly expanded in Alzheimer's disease (AD) research, offering a sensitive, scalable, and cost-effective alternative to traditional neuropsychological tests. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. 1 key finding →
Design: longitudinal study Participants: 20,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Bilingualism has been linked to improved executive function and delayed onset of dementia, but it is unknown whether similar benefits can be obtained later in life through deliberate intervention. 3 key findings →
Design: randomized controlled trial Participants: 76 Evidence: high
Full summary, score breakdown and related studies → Original source
This study will develop and test novel in-home technology to improve family caregiving relationships. 1 key finding →
Design: randomized controlled trial Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source
Our results corroborate the positive effect of pb-CT and its maintenance primarily on memory in HE and MCI participants that did not seem to be potentiated by RT. 5 key findings →
Participants: 348 Evidence: high
Full summary, score breakdown and related studies → Original source
Overall, this cross-cultural feasibility study in Japanese users demonstrated that the various engagement metrics were significantly correlated, and greater engagement was related to improved nutrition scores and increased time exercising. 5 key findings →
Design: longitudinal study Participants: 559 Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 29,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,380 records, built mostly from automated pulls of Europe PMC (63.3% of the library) and OpenAlex (17.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →